Claims for Patent: 8,357,697

Summary for Patent: 8,357,697

Title:	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquin- olin-2-ol compounds and methods relating thereto
Abstract:	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquin- olin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure: ##STR00001## wherein R.sub.1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.
Inventor(s):	Gano; Kyle W. (San Diego, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	13/237,709
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,357,697
Patent Claims:	1. A method of treating a hyperkinetic disorder, said method comprising administering to a subject a pharmaceutically effective amount of a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester or a pharmaceutically acceptable salt or solvate thereof. 2. The method according to claim 1 wherein the hyperkinetic disorder is Huntington's disease, tardive dyskinesia, Tourette's syndrome or tics. 3. The method according to claim 1 wherein the hyperkinetic disorder is Huntington's disease. 4. The method according to claim 1 wherein the hyperkinetic disorder is tardive dyskinesia. 5. The method according to claim 1 wherein the hyperkinetic disorder is Tourette's syndrome. 6. The method according to claim 1 wherein the hyperkinetic disorder is tics. 7. A method for inhibiting monoamine transporter isoform 2 (VMAT2) in a subject comprising administering to the subject a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier or diluent and (b) (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester or a pharmaceutically acceptable salt or solvate thereof.